| Document |
Document Title |
|
WO/2022/246929A1 |
The present invention relates to the technical field of drug synthesis, and provides a preparation method for an ABT-737 key intermediate and a preparation method for ABT-737. A compound having a structure as represented by formula I is ...
|
|
WO/2022/245124A1 |
The present invention relates to an ethene compound in a novel structure, a pharmaceutically acceptable salt thereof, or an N-oxide thereof, which each act as an estrogen-related receptor β/γ (ERRβ/γ) inverse agonist, and a pharmaceu...
|
|
WO/2022/246116A2 |
Provided herein are antibody-based antiviruses comprising a fusion protein that comprises a transmembrane polypeptide and an antibody which binds to a surface protein of a virus. Further provided herein are antibody-based antiviruses for...
|
|
WO/2022/242424A1 |
Disclosed are a purification method, system and detection method for N-methylmorpholine N-oxide (NMMO) and an obtained NMMO. The NMMO is derived from a crude product of NMMO prepared by reacting N-methylmorpholine with hydrogen peroxide....
|
|
WO/2022/245627A1 |
In one aspect, the application relates to sulfonyl chalcogenide urea derivatives of Formula II, including sulfonyl thioureas and sulfonyl selenoureas, and methods of making the same, wherein the methods can be carried out under mild cond...
|
|
WO/2022/240992A1 |
Described herein are TRPML1inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of TRPML1-mediated disorders or diseases.
|
|
WO/2022/237903A1 |
Provided are a quinazoline compound and an application thereof. Specifically provided is a quinazoline compound as shown in formula I. The compound is novel in structure and has a good inhibitory effect on cell factors TNF-α, IL-6, and ...
|
|
WO/2022/240277A1 |
The invention relates to novel compounds of formulae (I) and (II), to the use thereof as a drug, particularly for the treatment of SARS-CoV-2, for the treatment of COVID-19 disease and any diseases related to beta-coronaviruses, and for ...
|
|
WO/2022/236133A1 |
Provided herein are fatty acid amide (FAAH) cleavable prodrugs of thyromimetics and pharmaceutical compositions comprising these compounds with at least one pharmaceutically acceptable excipient further comprising a peripherally restrict...
|
|
WO/2022/230354A1 |
The purpose of the present invention is to provide a compound that can be suitably used in a fluorochrome or similar, a novel fluorochrome and kit for conveniently detecting cells, and a novel method for conveniently detecting cells or s...
|
|
WO/2022/232518A1 |
A pharmaceutical composition includes calxinin formulated for treating a viral infection. The pharmaceutical composition may be used to treat a subject having, or at risk of having, a viral infection. In some embodiments, the viral infec...
|
|
WO/2022/227743A1 |
The present invention relates to the technical field of medicines, and provides a memantine urea derivative, a preparation method therefore, and an application thereof. The memantine urea derivative provided by the present invention has ...
|
|
WO/2022/218348A1 |
This invention provides a new synthesis method of lactam compounds, which is characterized in that, the method uses sodium chlorite as an oxidant, and under the catalysis of carbon dioxide, oxidizes cyclic amine compounds to lactam compo...
|
|
WO/2022/221688A1 |
The present invention provides, among other things, a novel class of cationic lipid compounds (e.g., cationic lipids having a structure according to Formula (I)) for in vivo delivery of therapeutic agents, such as nucleic acids. It is co...
|
|
WO/2022/214137A1 |
The invention relates to a chemical compound of the general formula (I), to the use of such a chemical compound in an electronic component, and an electronic component comprising such a chemical compound.
|
|
WO/2022/213200A1 |
The present invention relates to a process preparing and therapeutic use of endocannabinoid-targeting prodrugs in a delivery system. In particular, the present invention relates to prodrugs of the endocannabinoid system- targeting molecu...
|
|
WO/2022/213198A1 |
There are provided Tissue Transglutaminase (TG2) inhibitor compounds, and compositions and methods of use thereof for the prevention or treatment of a disease state mediated by TG2, such as a cancer, a neurodegenerative disease such as H...
|
|
WO/2022/208545A1 |
The present invention discloses a process for the hydrogenation of imines of Formula I by palladium-based catalyst to provide product of Formula II with more than 95% conversion of substrate and more than 95% of desired hydrogenated prod...
|
|
WO/2022/204080A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2022/204046A1 |
Substituted naphthyl p38α mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and the use of the substituted naphthyl p38α mitogen-activated protein kinase inhibitors and pharmaceutical compositions thereo...
|
|
WO/2022/197798A1 |
Provided herein are methods and compositions for the treatment of diseases of ACTH excess, such as Cushing's disease, ectopic ACTH syndrome, and congenital adrenal hyperplasia.
|
|
WO/2022/190047A1 |
The present invention relates to a novel alternating diameter flow reactor for continuous - flow reactions, a system for continuous-flow reactions (as shown in Figure 1) comprising said alternating diameter flow reactor, a method for the...
|
|
WO/2022/189810A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds are papain-like protease (PLpro) inhibitors.
|
|
WO/2022/192562A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
|
|
WO/2022/189636A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt, hydrate, or isomer thereof. The invention also provides pharmaceutical compositions comprising the compounds of formula (I) as well as their ...
|
|
WO/2022/192162A1 |
Pharmaceutical compositions of the invention comprise heteroaromatic compounds having a disease-modifying action in the treatment of fungal infections and diseases associated with fungal infection.
|
|
WO/2022/187206A1 |
Disclosed herein are novel dual-target compounds that bind at both the mu-opioid receptor (MOR) and dopamine D3 receptors (D3R) to provide MOR-mediated analgesia, while minimizing addictive liability through D3R antagonism/partial agonis...
|
|
WO/2022/186162A1 |
The purpose of the present invention is to provide a method for producing a nucleophilic reaction product, the method being capable of using a halogenated carbonyl compound for the reaction without requiring isolation thereof, while bein...
|
|
WO/2022/185227A1 |
The present invention relates to novel Formyl Peptide Receptor subtype 2 (FPR2) agonist compounds and their use in the recovery of the inflammatory phenomena in which said receptor is involved, particularly in the context of the treatmen...
|
|
WO/2022/178228A1 |
The invention provides arylthioether acetamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as bacterial infections, and in inhibiting LpxA activity.
|
|
WO/2022/174525A1 |
The present invention relates to the fields of medicinal chemistry and pharmacotherapeutics, and in particular to a compound, a preparation method therefor and a use thereof, relating to the technical field of pharmacy. Provided are a co...
|
|
WO/2022/170834A1 |
Disclosed in the present invention is the use of an ionizable cationic lipid analog material as a protein drug delivery carrier. The cationic lipid analog material of the present invention has an efficient capability of intracellular del...
|
|
WO/2022/170835A1 |
Disclosed in the present invention is the application of an ionizable cationic lipid analogue material as a nucleic acid drug delivery vector or a transfection reagent. The cationic lipid analogue material of the present invention can ef...
|
|
WO/2022/168884A1 |
The present invention provides a novel cationic lipid having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof. (In ...
|
|
WO/2022/166994A1 |
Provided in the present invention are a naphthyl urea compound, a preparation method therefor and the use thereof. A naphthyl urea parent nucleus group with a biological activity contained in the naphthyl urea compound is further chemica...
|
|
WO/2022/163209A1 |
A carbon dioxide absorber which comprises an amine compound (A) having a heterocyclic structure (X) selected from among oxygen-containing heterocyclic structures and sulfur-containing heterocyclic structures and which has a content of th...
|
|
WO/2022/160466A1 |
A 2-cyanoacrylate compound and use thereof for preventing and treating fungal diseases of crops, belonging to the field of fungicides. The 2-cyanoacrylate compound has good fungicidal activity, particularly has good fungicidal activity a...
|
|
WO/2022/159445A1 |
The present disclosure is generally directed to activators of lipoprotein lipase useful in the treatment of diseases and disorders modulated by said enzyme and having the Formula (I), or a pharmaceutically acceptable salt, isomer, solvat...
|
|
WO/2022/153306A1 |
The present invention is directed to compounds having anti quorum sensing activity, anti-inflammatory activity or both, compositions comprising same, and methods of using same, such for treating a subject afflicted with a disease.
|
|
WO/2022/149618A1 |
The present invention provides a method for producing a compound having alkylated acidic functional groups. The method includes alkylating acidic functional groups by reacting, in a mixture containing a compound having two or more types ...
|
|
WO/2022/149617A1 |
The present invention provides a library which comprises from 1 × 102 to 1 × 108 compounds; the compounds have a structure in which a first core block (first CB), a first linker (first L) and a second core block (second CB) are covalen...
|
|
WO/2022/145923A1 |
The present invention relates to a pharmaceutical composition which is for preventing or treating viral infections and contains a piperlongumine-based compound as an active ingredient. Specifically, the piperlongumine-based compound acco...
|
|
WO/2022/145707A1 |
The present invention provides a novel piperlongumine-based compound, and an immunomodulator and a health functional food for immunomodulation, which comprise the compound or a pharmaceutically acceptable salt or solvate thereof as an ac...
|
|
WO/2022/144511A1 |
The invention relates to an ionic liquid comprising an anion of formula (I) and at least one onium cation, said ionic liquid having a colour of less than 115 Hazen units on the APHA scale. The invention also relates to a method for purif...
|
|
WO/2022/133544A1 |
Cannabidiol (CBD) cannabinoids and CBD cannabinoid analogues with, inter alia, antimicrobial activity, synthetic methods for the preparation thereof and medical uses and formulations containing same.
|
|
WO/2022/136641A1 |
The present invention generally relates to the field of ionizable (also termed cationic) lipids, and in particular provides a novel type of such lipids as represented by formula (I). The present invention further provides methods for mak...
|
|
WO/2022/138931A1 |
Provided is a compound represented by general formula (B1). Also provided is a corrosion inhibitor (B) including one or more selected from compounds represented by general formula (B1). Further provided is a lubricant composition includi...
|
|
WO/2022/130352A1 |
Present invention relates to compounds of general formula (I), their tautomeric forms, stereoisomers, pharmaceutically acceptable salts and pharmaceutical composition containing them. Invention also relates to process for the preparation...
|
|
WO/2022/129933A1 |
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ring A, Ring B, Ring C, R1, R2, R3, R4, R5, L, m, n, and p are as defined herein. The compounds are modulators of G-protein coupled rec...
|
|
WO/2022/129047A2 |
The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorder...
|
